on 25 Apr 2023
Last Applicant/ Owned by
302 East Pettigrew Street
Durham
NC
277013712
Serial Number
97117510 filed on 10th Nov 2021
Registration Number
7034224 registered on 25th Apr 2023
Correspondent Address
Eva Gullick Frongello
Filing Basis
1. filed as use application
2. use application currently
Disclaimer
"BIOSCIENCES"
research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic disease, gene therapy and cell therapy; pharmaceutical research and development services; Scientific research; scientific research in genetic, medical, pharmaceutical and veterinary fields; scientific research in chemistry, biology, biochemistRead More
Medical services, namely, cellular immunotherapy treatments utilizing chimeric antigen receptor t cells for use in treating disease, namely, the treatment of cancer
25th Feb 2016
25th Feb 2016
research in the fields of genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, genetic disease, gene therapy and cell therapy; pharmaceutical research and development services; Scientific research; scientific research in genetic, medical, pharmaceutical and veterinary fields; scientific research in chemistry, biology, biochemistry, molecular biology, bacteriology; scientific analysis in the field of immunotherapy; scientific research in the field of cellular immunotherapy utilizing chimeric antigen receptor t cells for use in treating cancer
11th Feb 2008
11th Feb 2008
pharmaceutical preparations, namely, cell therapy products utilizing t-cell therapy for use in treating disease; cell-based immunotherapeutic treatment by way of genetically modified cells for use in human therapeutics and the treatment of cancer; pharmaceuticals for the treatment of cancer; pharmaceutical preparations in the nature of genetically modified cells, namely, genetically modified immune cells for use in human therapeutics and in the treatment of cancer; pharmaceutical and biological preparations based on gene, genome and cellular editing, modulation, modification, engineering, regulation, repair and therapy for use in human therapeutics, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of cardiovascular, central nervous system, endocrine, gastrointestinal, genetic immunological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmological, psychiatric, respiratory, urogenital, urological, hematologic and viral diseases and disorders; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the treatment of erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications, namely, antifungal preparations, dermatological preparations, smoking cessation preparations and tissue repair preparations; engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, CAR T-cell preparations, T-cell preparations, B-cell preparations, Treg preparations, and NK cell preparations, all for clinical use, medical use, clinical laboratory use, and medical laboratory use
25th Feb 2016
25th Feb 2016
genome editing reagents for research purposes; Chemical, biochemical, biotechnological products intended for industry, agriculture, horticulture, namely, polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors; chemical, biochemical, biotechnological and bacteriological products intended for research laboratories and control laboratories, namely, polypeptides for in vivo and in vitro genetic engineering; Biochemicals and biologics, namely, engineered proteins for gene regulation, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, gene modification, and gene correction, all for use in scientific research, pharmaceutical research, agricultural biotechnology, diagnostics, and industrial biotechnology; engineered proteins for use in scientific research and analysis relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, CAR T-cell preparations, T-cell preparations, B-cell preparations, Treg preparations, and NK cell preparations, all for use in scientific research and analysis and diagno
11th Feb 2008
11th Feb 2008
No 97117510
No Service Mark
No 30304-00002
No
No
No
No
No
No
No
No
09.01.04 -
Ribbons, bows
26.01.21 -
Circles that are totally or partially shaded
The mark consists of the stylized words "PRECISION BIOSCIENCES" to the right of a stylized ribbon within a circle.
| Status Date | Action Taken |
|---|---|
| 08th May 2023 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| 08th May 2023 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| 08th May 2023 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| 08th May 2023 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| 08th May 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| 25th Apr 2023 | REGISTERED-PRINCIPAL REGISTER |
| 25th Apr 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 06th Mar 2023 | JURISDICTION RESTORED TO EXAMINING ATTORNEY |
| 06th Mar 2023 | LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN |
| 06th Mar 2023 | ATTORNEY REVIEW COMPLETED |
